Rohto Pharmaceutical Aims for 464 Billion Yen in Sales for Fiscal 2032
MT Newswires Live
Yesterday
Rohto Pharmaceutical (TYO:4527) has set a sales target of 464 billion yen for fiscal 2032 under its updated long-term growth strategy, according to a Tokyo bourse filing on Friday.
Other goals for the fiscal year include operating profit of 59.8 billion yen, operating profit margin of 12.9%, an overseas sales ratio of 56% and a dividend payout ratio of 40%.
For fiscal 2031, the company updated its targets to 444 billion yen in sales, 56.8 billion yen in operating profit, 12.8% in operating profit margin and 18% in EBITDA margin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.